Lymphoma Articles
-
Clonality Analysis Service: A Paradigm Shift in Disease Diagnosis and Treatment
Understanding Clonality Analysis Clonality refers to the origin of a cell population from a single 'parent' or progenitor cell through asexual reproduction or division. This concept is vital in cancer studies as it helps track the development of tumor cells from a single mutated cell. Clonality analysis is thus essential in understanding the evolution and the spread of cancerous cells in a ...
-
CD19: One of The Most Important Targets for Car-T Cell Therapy
What is CD19 Understanding CD19: Definition and Role in the Immune System CD19, also known as Cluster of Differentiation 19, is a cell surface protein belonging to the immunoglobulin superfamily. It serves as a crucial marker for B cells, playing a pivotal role in the human immune system. While predominantly found on the surface of B cells, CD19 is rarely expressed on other immune cells. Its ...
-
Inflammation, Immunity and Cancer
Relationship Between Immunity, Inflammation and Cancer Immunity is an act of self-protection of the body. The immune response is divided into specific and non-specific. The antigen and antibody responses are generally referred to as specific immune responses, which require the participation of B cells and T cells. Other immune cells such as macrophages and NK cells mediate non-specific immune ...
-
FDA Approved ALK Inhibitors for ALK-Positive Non-Small Cell Lung Cancer
Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a relatively rare and dangerous subtype, with patients suffering from a high incidence rate of brain metastases. Statistics show that about 55% of ALK-positive advanced NSCLC patients will develop brain metastases during ...
By BOC Sciences
-
Natural killer cell reprogramming with chimeric immune receptors
Abstract Natural killer (NK) cells are emerging as a new tool for cell therapy of cancer. However, some cancer subtypes are relatively resistant to NK cell cytotoxicity. Expression of anti-CD19 chimeric signaling receptors can enhance NK-cell reactivity against CD19+ leukemia and lymphoma cells. Here we describe a method to enforce expression of such receptors in human NK cells relying on ...
By Nkarta, Inc.
-
The Life Cycle of Epstein-Barr Virus
Epstein-Barr Virus (EBV) is a large enveloped virus of double-stranded DNA among the eight known herpesviruses. After EBV infection of cells, it accumulates in the nucleus, and there are two life cycles, with alternating phases of latency and lysis. EBV infection is associated with a variety of human malignancies and malignant tissue proliferative diseases, including malignant lymphoma, gastric ...
-
A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data
AFM13 is a first-in-class tetravalent, bispecific NK cell engager that binds to CD30 on tumor cells and CD16A on NK cells. By engaging CD16-positive NK cells, AFM13 leads to NK cell-mediated killing of tumor cells.1 Pembrolizumab (Keytruda®) is approved in patients with R/R classical Hodgkin lymphoma as monotherapy. AFM13 showed single agent clinical activity with solid safety profile in a ...
By Affimed GmbH
-
Enhancing Oncology Model: New CMS value-based payment model aims to improve health equity and patient-centered care
Just days before the sunset of the CMS Oncology Care Model, CMS announced its new Enhancing Oncology Model (EOM), the new value-based care oncology payment model. Rolled out as part of the Biden-Harris Administration’s Cancer Moonshot, the goal of EOM is to improve the experience of cancer patients, while advancing health equity and increasing access to care, as well as reducing Medicare ...
-
Effect of interferon receptor pathway on CAR-T cell-mediated killing of solid tumors
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen ...
-
Antibody-peptide epitope conjugate (APEC), another disguise for ADC
Background Tumor immunotherapies compose immune checkpoint inhibitors, therapeutic antibodies, tumor vaccines, cellular therapies, and so on. However, each has its own set of issues, such as the fact that CAR-T therapy is an individual therapy that is costly; immune checkpoint inhibitors are highly effective, but only in some patients. The researchers expose us to a radically different way of ...
-
The 3rd AIDS patient is "cured"! Has mankind finally conquered AIDS?
At an academic conference on Feb 15, U.S. experts announced the world's first female AIDS "cure," making it the third case of HIV infection to be cured. After therapy and withdrawal of antiviral drugs, HIVs were not identified in the patient's body for more than 14 months, indicating that the virus was in complete remission, according to academics. The key to this patient's recovery was a blood ...
-
Three generations of ADC: Nearly a decade of development-PII
Kadcyla and second-generation non-cleavable linkers Alternative linker design methodologies are still under development. Immunogen discovered a very powerful ADC by an accidental discovery. The lysine residue of trastuzumab is linked to DM1 via a non-cleavable linker containing N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), an ADC (T-DM1, Kadcyla) authorized by the FDA in ...
-
Three generations of ADC Nearly a decade of development-PIII
Novel cytotoxic drugs New cytotoxic drugs have been developed to target cancer cells with low antigen expression or resistance to auristatins or maytansinoids. For this purpose, PBD dimers have been developed, which have a molecular structure containing two alkylated imine functional groups capable of forming covalent bonds with DNA.PBD dimers are about 50-100 times more potent than conventional ...
-
New Study Findings about Glycoprotein PTGDS
Glycoprotein prostaglandin D2 synthase (PTGDS) is a member of the lipocalcitonin superfamily that plays a dual role in prostaglandin metabolism and lipid transport. PTGDS is involved in various cellular processes including solid tumorigenesis, but its role in tumorigenesis is paradoxical, and the significance of PTGDS in hematologic malignancies is not clear. The aim of this new study was to ...
By CD BioGlyco.
-
What are the ADC drugs?
Antibody-drug conjugates (ADCs) continue to rise at home and abroad, but ADCs are not a new thing. Why has ADC been surging for so many years? What kind of magic power it contains, and what makes its growth path so tortuous? Let's take a brief look at the magical "magic bullet"-ADC. ADC (antibody-conjugated drug) is not a new concept. As early as the early 20th century, the Nobel Prize winner ...
By BOC Sciences
-
Israeli hospital pilots rapid diagnostics of blood cancer with Sight Diagnostics
Israeli-founded firm Sight Diagnostics, the company that uses AI and cutting-edge hardware to deliver rapid, complete blood count results, has signed a new research agreement with Jerusalem’s Shaare Zedek Medical Center to identify the possibility of blood cancer using a combination of images and data collected from Sight’s OLO device and patient clinical information provided by the ...
-
The Problem with Gene-Modified Cell Therapy Manufacturing
Gene-modified cell therapies (GMCTs) represent the most effective therapeutic platform for many patients with advanced diseases including relapsed and refractory leukemia, non-Hodgkin lymphoma, and other blood cancers [1]. Specifically, chimeric antigen receptor T cell (CAR-T) therapies targeting CD19 have demonstrated remarkable responses and possibly cures in patients with advanced acute ...
By Indee Labs
-
New Cell Contenders in the CAR Field (Part 1)
Chimeric antigen receptor T-cells (CAR-T) are one of the first clinically approved therapies to take full advantage of the most significant advancements in immunology and genetic engineering. The resulting therapeutics have been shown to produce remission rates exceeding 80% in patients with CD19+ B-cell lymphoma, making them nothing short of remarkable [1]. Unfortunately, CAR-T cells seem ...
By Indee Labs
-
Overview Of SFA Therapeutics
SFA Therapeutics’ CEO Dr Ira Spector presents an overview of the company and its platform technology SFA Overview Presentation on YouTube Introduction to SFA Liver Disease and Oncology Programs. SFA Oncology More information here We received US Patent 10,143,669B2; to prevent Hepatitis B progression to HCC, a liver cancer that affects 400 million patients and causes 1 million cancer ...
-
What is the meaning of neoplastic disease?
Neoplasia is the abnormal growth and proliferation of abnormal cells or abnormal amounts of cells due to a benign or malignant process. There can be benign tumors, or neoplasms, and malignant ones. Remember that it's the malignant tumors, or cancer, that can metastasize, which is when cancer spreads around the body. Leukemia is used for lymphoid neoplasms presenting with widespread involvement ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you